Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.41 |
| ▸ | CA2 | P00918 | 5/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.31 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.31 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.31 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.31 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.31 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 2/20 | 0.30 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28932722 | 0.93 | CA2 (0.37) | CA1CA2 | |
| SCHEMBL27994173 | 0.76 | CA1 (0.42) | CA1CA2PSEN1PSEN2APH1B | |
| SCHEMBL7478287 | 0.75 | ALDH1A1 (0.49) | CA1CA2ALDH1A1HTT | |
| SCHEMBL1645144 | 0.74 | PSEN1 (0.49) | CA1CA2ALDH1A1HTTCA12 | |
| SCHEMBL28202636 | 0.74 | ALDH1A1 (0.41) | CA1CA2ALDH1A1HTTCA12 | |
| SCHEMBL29843316 | 0.71 | CA1 (0.38) | CA1CA2ALDH1A1HTTPSEN1 | |
| SCHEMBL7332760 | 0.70 | FKBP1A (0.44) | ALDH1A1 | |
| SCHEMBL1645900 | 0.70 | FFAR1 (0.35) | CA1CA2ALDH1A1HTTPSEN1 | |
| SCHEMBL1647207 | 0.69 | PSEN1 (0.53) | CA1CA2ALDH1A1PSEN1PSEN2 | |
| SCHEMBL20600047 | 0.69 | CA1 (0.37) | CA1CA2PSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11471455-B2 | Compounds and compositions for treating conditions associated with APJ receptor activity | ANNAPURNA BIO, INC. (US) | 2022-10-18 | — | — | US | claimed |
| CN-113490668-B | Compounds and compositions for the treatment of diseases associated with APJ receptor activity | 安娜普尔纳生物股份有限公司 | 2025-02-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11471455-B2 | Compounds and compositions for treating conditions associated with APJ receptor activity | APLNR, AGTR1, AGTR2 | CA1 3132/4885CA2 962/4885EPHX1 893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.